About Cognoptix
A simple scan detects beta-amyloid in the lens of the eye, potentially leading to early diagnosis of Alzheimer’s Disease
Cognoptix is developing an affordable, non-invasive screening test patients can take – in minutes – at their doctor’s office
The key to effective preventive therapy and treatment of Alzheimer’s is the creation of an “early warning system” for the disease, before it progresses to the point where treatment options are limited. Cognoptix’ technology has demonstrated successful early clinical results as the company develops its diagnostic platform, which consists of a laser eye scanning device combined with an ophthalmic ointment which specifically identifies Alzheimer’s-related proteins found in the lens of the eye.
Our Mission
To aid in the early detection, diagnosis and prognosis of Alzheimer’s disease through a simple, non-invasive laser eye scan.
An Early Warning System to Enable Swift Intervention
Cognoptix’ goal is to provide clinicians with a highly accurate, reliable, inexpensive, convenient and widely available test that can be performed quickly on-site in the comfort of a physician’s office, to enable swift intervention and early treatment.
The company is interested in partnering with major pharmaceutical companies, licensing its laser eye scanning technology for use in the development of Alzheimer’s drugs, as an enabling technology for patient titration and monitoring in clinical trials.
